Fifty years ago, a curative combination chemotherapy to diffuse large B-cell lymphoma (DLBCL) called CHOP quickly became first-line therapy for this common disease. Twenty-five years ago, the immunotherapy rituximab (an antibody directed to a B-cell surface marker called CD20) was added to CHOP to form RCHOP. This was a huge advance for first-line therapy, but it added some additional toxicity ...
To access content, please login or purchase a subscription.
